Organoprotective effects of glucagon-like peptide-1 receptor agonists with regard to findings of evidencebased cardiovascular safety studies

Медицинский совет

Yu. Sh. Khalimov¹  V. G. Kuzmich¹ 

[1]Military Medical Academy named after S.M. Kirov

关键词: diabetes mellitus;    incretins;    glucagon-like peptide-1 receptor agonists;    obesity;    cardiovascular risk;    cardiovascular complications;    renal complications;   

DOI  :  10.21518/2079-701X-2019-21-189-197

来源: DOAJ

【 摘 要 】

The article discusses the potential opportunities for impact of antidiabetic drugs from the group of glucagon-like peptide-1 (GLP- 1) receptor agonists on the risks of development and progression of cardiovascular complications in patients with type 2 diabetes mellitus (T2DM) and their possible role in increasing the patients’ expectancy and quality of life. The existing differences between the drugs of this class should be taken into account in using personalized approach to therapy, developing and introducing new guidelines for specialized medical care for patients with type 2 diabetes into clinical practice. The article presented data on the efficacy and safety of the use of GLP-1 receptor agonists and discusses data on the possible mechanisms of non-glycemic effects underlying their cardio and nephroprotection. The features of pharmacological characteristics affecting the clinical efficacy and development of side effects are considered. The article also provides data from randomized clinical trials of various GLP-1 receptor agonists that demonstrate the positive effect of drugs of this class on cardiovascular and nephrological outcomes in patients with type 2 diabetes.

【 授权许可】

Unknown